CSHL1 Inhibitors constitute a specialized class of chemical compounds designed to selectively impede the activity of the CSHL1 gene product. CSHL1, or Cold Shock Domain-Containing Protein L1, is a member of the cold shock protein family, characterized by the presence of a conserved cold shock domain. These proteins play diverse roles in cellular processes, including RNA binding, transcriptional regulation, and response to environmental stress. The development of inhibitors targeting CSHL1 is crucial for scientific investigations, providing researchers with specific tools to explore the molecular functions and regulatory roles associated with this particular cold shock protein variant.
The synthesis and optimization of CSHL1 inhibitors require a comprehensive understanding of the gene product's structural characteristics and its interactions within cellular pathways. These inhibitors are meticulously designed for specificity, aiming to selectively bind to key regions of CSHL1 and interfere with its normal functions. By employing CSHL1 inhibitors in experimental settings, researchers can explore the consequences of gene product inhibition on cellular processes, shedding light on the specific molecular pathways influenced by CSHL1. The study of CSHL1 inhibitors contributes to the broader exploration of cold shock proteins, providing insights into the intricate molecular machinery that underlies cellular responses to environmental cues and stress conditions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Mitomycin C cross-links DNA, inhibiting transcription and potentially reducing the synthesis of CSHL1 mRNA. | ||||||
Puromycin dihydrochloride | 58-58-2 | sc-108071 sc-108071B sc-108071C sc-108071A | 25 mg 250 mg 1 g 50 mg | $42.00 $214.00 $832.00 $66.00 | 394 | |
Puromycin induces premature termination of protein synthesis, impacting translation and lowering CSHL1 levels. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin X2, similar to Actinomycin D, binds to DNA and inhibits transcription, resulting in decreased CSHL1 mRNA. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $69.00 $266.00 | 8 | |
Mycophenolic acid inhibits inosine monophosphate dehydrogenase, indirectly affecting CSHL1 expression by disrupting purine synthesis. | ||||||
Blasticidin S Hydrochloride | 3513-03-9 | sc-204655A sc-204655 | 25 mg 100 mg | $367.00 $520.00 | 20 | |
Blasticidin S induces premature termination during translation, inhibiting protein synthesis and reducing CSHL1 levels. | ||||||
Ellipticine | 519-23-3 | sc-200878 sc-200878A | 10 mg 50 mg | $145.00 $569.00 | 4 | |
Ellipticine intercalates into DNA, disrupting DNA structure and inhibiting transcription, leading to decreased CSHL1 mRNA. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits DNA topoisomerase I, inducing DNA damage and inhibiting transcription, leading to decreased CSHL1 mRNA. | ||||||
Ellagic Acid, Dihydrate | 476-66-4 | sc-202598 sc-202598A sc-202598B sc-202598C | 500 mg 5 g 25 g 100 g | $58.00 $95.00 $245.00 $727.00 | 8 | |
Ellagic Acid may inhibit CSHL1 expression through its reported anti-cancer and anti-inflammatory properties. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
5-Fluorouracil interferes with RNA synthesis, affecting the expression of CSHL1 by disrupting the production of mRNA. | ||||||